BioDiscovery, A Bionano Genomics Company, is proud to participate in the upcoming 47th American Cytogenomics Conference, Hilton Head Island, SC May 15-18, 2022.
View the ACC 2022 program to learn if this is the right meeting for you!
When you're ready, register for the meeting here.
LEARN 📚Decoding Cancer Complexity
The latest NxClinical software 6.2 release adds three measures of genomic instability for homologous recombination repair deficiency (HRD) in solid tumors:
- Loss of Heterozygosity (LOH)
- Telomeric Allelic Imbalance (TAI)
- Large-Scale State Transitions (LST)
Chief Informatics Officer, Bionano Genomics
Collaboration is the driver behind the new Illumina InfiniumTM Global Diversity Array with Cytogenetics Content (GDA-Cyto) coupled with Bionano’s NxClinical analysis software. The GDA-Cyto offers genome-wide coverage at exon resolution across high-value clinical regions enabling laboratories to review cases faster and remain more economical than current workflows. Learn more about this new array platform and software offering during this co-presented ACC exhibitor spotlight.Daniel Saul and Jackie Hagan
Daniel Saul, Technical Sales Director, Bionano Genomics Jackie Hagan, Product Manager, Human Genotyping Arrays, Illumina
This year BioDiscovery will be joining our parent company, Bionano Genomics, in the exhibit hall to discuss our software solutions for clinical and translational research.
VISIT THE BIONANO BOOTH TO EXPLORE OUR SOLUTIONS
Bionano is one team working together to transform the way the world sees the genome.